Recent Updates
Recently added Catalysts
TBPH Positive Sentiment

Theravance Biopharma to Participate in an Upcoming Investor Conference Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a fireside chat at the Jones Healthcare and Technology Innovation Conference in Las...

Key Takeaway: Theravance Biopharma, Inc. (TBPH) is participating in the Jones Healthcare and Technology Innovation Conference in Las Vegas, scheduled for April 9. Senior management will hold one-on-one meetings and a fireside chat during the event. The company plans to provide a recording of the event for those who cannot attend. Theravance focuses on creating impactful medicines, including its FDA-approved product for COPD and a late-stage investigational therapy for neurogenic orthostatic hypotension.
Price reaction · baseline $9.23 (2025-03-28 close) · clean, no other TBPH news in the window
day 0 close · peak
-3.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • Theravance Biopharma is actively engaging with investors at a significant conference.
  • The recording of the event will be available for continued visibility.
  • The company showcases its commitment to shareholder value and innovation.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+34%
120-day peak, hindsight
Typical move
0.1%
average across 3 past catalysts
Cash runway
~167 mo
Minimal dilution risk
Lead asset
Revefenacin
Phase 2 · COPD

Full Press Release Details

DUBLIN , March 31, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ) will participate in a fireside chat at the Jones Healthcare and Technology Innovation Conference in Las Vegas on Wednesday, April 9 at 11:30 am PDT ( 2:30 pm EDT / 6:30 PM GMT ).
Members of Theravance Biopharma senior management will also be hosting one-on-one meetings at the conference. To attend the fireside chat and schedule meetings with management, please contact your Jones representative or email Yuki Gonzalez , Vice President, Marketing & Corporate Access ( [email protected] ).
A recording of the event will be available after the conference and may be accessed by visiting Theravance.com , under the Investors section, Events and Presentations. The recording will be archived on the Company's website for 30 days.
About Theravance Biopharma
Theravance Biopharma, Inc.'s focus is to deliver Medicines that Make a Difference ® in people's lives. In pursuit of its purpose, Theravance Biopharma leverages decades of expertise, which has led to the development of FDA-approved YUPELRI ® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Ampreloxetine, its late-stage investigational once-daily norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA), has the potential to be a first in class therapy effective in treating a constellation of cardinal symptoms in MSA patients. The Company is committed to creating/driving shareholder value.
For more information, please visit www.theravance.com .
THERAVANCE BIOPHARMA ® , THERAVANCE ® and the Cross/Star logo are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries).
YUPELRI ® is a registered trademark of Mylan Specialty L.P., a Viatris company. Trademarks, trade names or service marks of other companies appearing in this press release are the property of their respective owners.

Frequently Asked Questions

When will Theravance Biopharma participate in the fireside chat?

Theravance Biopharma will participate in the chat on April 9 at 11:30 am PDT.

How can I attend the Theravance fireside chat?

To attend, contact your Jones representative or email Yuki Gonzalez.

Where can I access the event recording?

The recording will be available on Theravance.com under the Investors section.

What is the main focus of Theravance Biopharma?

Theravance Biopharma aims to deliver innovative medicines that improve lives.

What is YUPELRI used for?

YUPELRI is indicated for the maintenance treatment of COPD patients.

Last updated: Mar 31, 2025